Circulation

JANUARY 27, 2025

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Peripheral Arterial Disease Stroke Strokes 81

DAIC

APRIL 9, 2025

tim.hodson Wed, 04/09/2025 - 14:38 April 9, 2025 Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced March 17, 2025 ), has now approved the updated label for Tryvio(aprocitentan). Hypertension.

Blood Pressure 52

Blood Pressure Hypertension Myocardial Infarction Kidney Disease 52

DAIC

JANUARY 8, 2025

tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S.

Blood Pressure 52

Blood Pressure Hypertension Kidney Disease BMI 52

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Hypertension, diabetes, hyperlipidemia, and chronic kidney disease are well-known cardiovascular risk factors for ICH. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.

Atrial Fibrillation 40

Atrial Fibrillation Hemorrhage Risk Factors Kidney Disease 40

DAIC

MARCH 25, 2025

tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

JUNE 28, 2024

milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidney disease (CKD) as well as hypertension and cardiovascular disease.

Kidney Disease 111

Kidney Disease Blood Pressure Cardiovascular Disease Hypertension 111

DAIC

MARCH 25, 2025

tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across t he KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52